APOE genotype results in differential effects on the peripheral clearance of amyloid-β42 in APOE knock-in and knock-out mice

Journal of Alzheimer's Disease

Volumn 21, Issue 2, 2010, Pages 403-409

  Sharman, Matthew J ^a,b,c   Morici, Michael ^b,c   Hone, Eugene ^b,c   Berger, Tamar ^b,c   Taddei, Kevin ^a,b,c   Martins, Ian J ^a,b,c   Lim, Wei Ling F ^b,c   Singh, Sajla ^a,b   Wenk, Markus R ^d   Ghiso, Jorge ^e   Buxbaum, Joseph D ^f   Gandy, Sam ^e   Martins, Ralph N ^a,b,c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid ; APOE genotype; peripheral sink hypothesis

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ALLELE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN; C57BL 6 MOUSE; CONTROLLED STUDY; GENOTYPE; HUMAN; IN VIVO STUDY; KIDNEY; KNOCKOUT MOUSE; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 77957358016     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100141     Document Type: Article

References (19)

1. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral antiAbeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98, 88508855.
2. Hone E, Martins IJ, Fonte J, Martins RN (2003) Apolipoprotein E influences amyloidbeta clearance from the murine periphery. J Alzheimers Dis 5, 18.
3. Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE,MartinsRN(1999)Apolipoprotein E promotes the binding and uptake of betaamyloid into Chinese hamster ovary cells in an isoformspecific manner. Neuroscience 90, 12171226.
4. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN (1997) Characterization of the binding of amyloidbeta peptide to cell culturederived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68, 721725.
5. La Du MJ, Lukens JR, Reardon CA, Getz GS (1997) Association of human, rat, and rabbit apolipoprotein E with betaamyloid. J Neurosci Res 49, 918.
6. La Du MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT (1995) Purification of apolipoprotein E attenuates isoformspecific binding to betaamyloid. J Biol Chem 270, 90399042.
7. La Du MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE (1994) Isoformspecific binding of apolipoprotein E to betaamyloid. J Biol Chem 269, 2340323406.
8. Hone E, Martins IJ, Jeoung M, Ji TH, Gandy SE, Martins RN (2005) Alzheimer's disease amyloidbeta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7, 303314.
9. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N (1999) Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 103, 15791586.
10. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL,Quarfordt SH,Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances dietinduced hypercholesterolemia and atherosclerosis. J Biol Chem 272, 1797217980.
11. Sullivan PM,MezdourH,Quarfordt SH,Maeda N(1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe2. J Clin Invest 102, 130135.
12. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 89, 44714475.
13. Martins IJ, Vilcheze C, Mortimer BC, Bittman R, Redgrave TG (1998) Sterol side chain length and structure affect the clearance of chylomicronlike lipid emulsions in rats andmice. J Lipid Res 39, 302312.
14. Gandy S, Almeida OP, Fonte J, Lim D, Waterrus A, Spry N, Flicker-L, Martins RN (2001) Chemical andropause and amyloidbeta peptide. JAMA 285, 21952196.
15. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B (2004) Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 279, 4589745908.
16. Weisgraber KH (1990) Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteinearginine interchange at residue 112. J Lipid Res 31, 15031511.
17. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280, 4323643242. (Pubitemid 43049290)
18. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloidbeta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 22642267.
19. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to betaamyloid. J Neurosci 23, 2933.